|
Lilly's Three-Year SURMOUNT-1 Data Demonstrates Tirzepatide’s Role in Diabetes Prevention
|
Written by: J. Smith |
Hits: 647
|
|
Novo Nordisk Advances Semaglutide in MASH Treatment Following ESSENCE Trial Success
|
Written by: J. Smith |
Hits: 745
|
|
Wegovy’s Lowest Dose Now Available in the U.S.
|
Written by: J. Smith |
Hits: 673
|
|
Dexcom Submits 15-Day G7 CGM to FDA for Approval
|
Written by: J. Smith |
Hits: 1677
|
|
Novo Nordisk’s Oral Semaglutide Reduces Cardiovascular Risk by 14% in SOUL Trial
|
Written by: J. Smith |
Hits: 745
|
|
Novo Nordisk Unveils Glucose-Sensitive Insulin to Reduce Hypoglycemia Risk
|
Written by: J. Smith |
Hits: 1260
|
|
FDA Reconsiders Tirzepatide Shortage Status
|
Written by: J. Smith |
Hits: 787
|
|
Teva Launches Authorized Generic of Victoza (liraglutide) in the U.S.
|
Written by: J. Smith |
Hits: 908
|
|
EU Recommends Wegovy® Label Update for Heart Failure in Obesity
|
Written by: J. Smith |
Hits: 1027
|
|
Innovative Health Research in Space with Dexcom G6 CGM on Polaris Dawn Mission
|
Written by: J. Smith |
Hits: 779
|
